PAY WITH VISA, MASTERCARD, INTERAC

Peptide intellectual property considerations: a Canadian guide

Authors

1012874pwpadmin
Researcher pipetting peptide solution in Canadian lab

Peptides are patentable in Canada. Full stop. The Patent Act does not exclude them, and CIPO’s March 2026 practice notice confirms that biomolecule claims survive examination when they satisfy novelty, inventive step, and utility and are framed as physical entities rather than abstract information. What trips up most teams is not eligibility itself but execution: a sequence listing filed in the wrong format, a claim that reads on a naturally occurring peptide, or uses language that inadvertently triggers the medical-treatment exclusion.

The short verdict for funding and licensing conversations:

  • Peptides with a defined structure and a demonstrated technical effect are patentable subject-matter in Canada.
  • Regulatory exclusivities (data protection, PM(NOC) linkage, Certificates of Supplementary Protection) stack on top of patent rights and must be planned in parallel.
  • Trade secrets and contracts protect what patents cannot, particularly manufacturing know-how.

Three rapid do / don’t items before you file or publish:

  1. Do prepare a WIPO ST.26-compliant sequence listing before or at the time of filing.
  2. Don’t present findings at a conference or post a preprint before your priority date is secured.
  3. Do instruct Canadian patent counsel before PCT national phase entry or any licence negotiation.

Table of Contents

What this guide covers and who should use it

This guide addresses patent filing and prosecution before the Canadian Intellectual Property Office (CIPO), sequence listing compliance under WIPO ST.26, the interplay between patent rights and regulatory exclusivities under the Patented Medicines (Notice of Compliance) Regulations (PM(NOC)), and the contractual frameworks that protect what patents leave exposed.

Who benefits most:

  • Discovery-stage researchers deciding when to publish versus when to file.
  • Preclinical and CMC teams assembling data packages for a first Canadian filing or PCT national phase entry.
  • Biotech founders preparing for seed or Series A diligence, where IP chain of title is scrutinised closely.
  • In-house and outside counsel advising on claim strategy, freedom-to-operate (FTO), or licence negotiations.

When to retain Canadian counsel:

  • Before any public disclosure, conference abstract, or preprint submission.
  • Before filing a PCT application or entering the Canadian national phase.
  • Before signing a collaboration agreement, material transfer agreement (MTA), or term sheet that touches foreground IP.

Pro Tip: IP strategy should be goal-oriented, not just “get a patent.” Decide up front whether the objective is market exclusivity, licensing revenue, or defensive freedom-to-operate, because that choice shapes which claims to pursue and which protections to layer underneath.

The medical-treatment exclusion

Canada excludes methods of medical treatment from patentable subject-matter. The risk for peptide therapeutics is real: a use claim framed as “a method of treating condition X by administering peptide Y” may be rejected if the claim requires the exercise of professional skill and judgment as an essential element. The fix is to frame use claims as “use of peptide Y for treating condition X” or “use of peptide Y in the manufacture of a medicament,” which are accepted formulations under Canadian practice.

“Professional judgment triggers the medical-treatment exclusion; avoid framing claims that require a health professional’s discretionary steps as essential elements of the claimed invention.”
CIPO, March 2026 practice notice on patentable subject-matter

Borderline cases worth knowing: Canadian Federal Court decisions on biotech subject-matter have generally upheld claims to isolated or modified biomolecules that differ meaningfully from their naturally occurring counterparts. A synthetic analogue with a non-natural amino acid substitution that confers improved proteolytic stability is a stronger candidate than a claim to the native sequence alone. The key is pairing the structural distinction with data showing the technical consequence.

Pro Tip: Frame claims to show a technical effect tied to the peptide’s structure — improved half-life, receptor selectivity, or solubility — rather than an abstract correlation between sequence and activity. That framing satisfies both the physicality requirement and the inventive step analysis.

Sequence listing and WIPO ST.26: what CIPO now requires

File your sequence listing in ST.26 electronic format. That is the rule for all Canadian applications filed after July 1, 2022, following CIPO’s amendments to the Patent Rules. The ST.26 standard replaced the older ST.25 format globally, and CIPO updated the relevant MOPOP chapters to reflect the change. For PCT applications, WIPO’s PCT resources govern the international filing stage; CIPO then applies its own ST.26 requirements at national phase entry.

A CIPO practice notice on sequence listings clarifies two points practitioners must internalise: the listing must be in electronic ST.26 XML form, and any paper copy previously on record must be formally withdrawn once an electronic listing is filed. Leaving both on record creates a formal defect that generates a requisition and delays prosecution.

Practical sequence file checklist:

  • Prepare the ST.26 XML file using WIPO’s SEQTOOL software or a validated vendor conversion service before or at filing.
  • Assign sequential SEQ ID numbers to every amino acid sequence of four or more residues that appears in the claims or description.
  • Include the mandatory general information fields: applicant name, application number (if known), and a statement confirming the listing contains no new matter relative to the application as filed.
  • If amending a sequence listing during prosecution, file a replacement listing with a clear statement that it introduces no new matter, and simultaneously withdraw the superseded version.
  • Validate the XML file against the ST.26 DTD before submission; CIPO will reject malformed files.
Requirement Detail Consequence of non-compliance
File format ST.26 XML (post-July 1, 2022 filings) Formal requisition; prosecution delay
Paper copy withdrawal Required once electronic listing is on record Defect; possible objection
SEQ ID numbering Sequential, all sequences ≥4 amino acid residues Examiner objection; potential support issues
No new matter statement Required on any replacement listing Rejection of amendment if omitted
PCT alignment ST.26 governs international phase; CIPO applies at national phase Inconsistency triggers requisition

Sequence listings filed with CIPO become publicly available through CIPO’s online database once the application publishes, typically 18 months from the priority date. That publication affects FTO searches: a competitor running a BLAST search against publicly available CIPO sequence data can identify your claimed sequences before grant. Plan your filing timing accordingly.

How to draft effective peptide claims for CIPO examination

Breadth and enforceability pull in opposite directions, and the best claim strategy for a peptide invention threads between them by filing multiple claim types, each supported by adequate data in the specification. A single sequence claim is rarely sufficient.

Sequence claims versus structural and compositional claims

A claim that reads “SEQ ID NO: 1” without further definition is the most common drafting error in peptide applications. CIPO examiners, applying purposive construction, may characterise such a claim as directed to information rather than a physical entity. The fix is straightforward: define the biomolecule with structural language (“a peptide comprising the amino acid sequence of SEQ ID NO: 1”), functional language (“a peptide that binds receptor X with an IC50 of less than Y nM”), or both. Functional claims need adequate support in the specification, including representative examples across the claimed functional range.

Derivative claims: salts, solvates, polymorphs, and enantiomers

When claiming a salt, solvate, or polymorph of a known peptide, include specific physical parameters: crystal form, X-ray powder diffraction (XRPD) patterns, melting point, or solubility data. CIPO and the courts look for non-routine advancement over the prior art, which in practice means comparative data showing an unexpected technical advantage. A polymorph with markedly improved aqueous solubility relative to the parent compound, documented with reproducible characterisation data, supports both inventiveness and utility.

Hands holding peptide salt vial with lab instruments

Claim type Key drafting requirement Common pitfall
Sequence / composition Structural definition beyond SEQ ID NO Claiming only the sequence number
Use / Swiss-style “Use of [peptide] for treating [condition]” Method-of-treatment framing
Formulation Specific excipient ratios or delivery system Insufficient support for claimed range
Salt / polymorph Physical parameters + unexpected benefit data No comparative data vs. parent compound
Process / manufacture Defined steps, reagents, conditions Overly broad without working examples

Use BLAST with amino acid similarity thresholds appropriate to the length and specificity of your peptide. For short peptides (under 20 residues), even a single substitution can place a sequence outside a prior-art claim’s scope, but it can also fall within a functional claim that covers “variants with at least 80% identity.” Map any hit against the actual claim language, not just the sequence disclosure, because a sequence in a patent’s description that is not in a claim does not block you.

Numbered steps for commissioning a professional FTO opinion:

  1. Define the exact molecule(s) and use(s) you intend to commercialise before briefing counsel.
  2. Provide counsel with all internal sequence data, synthesis routes, and proposed indications.
  3. Request a landscape search covering PatentScope, Espacenet, CIPO, and GenBank.
  4. Ask for a claim map that identifies each potentially blocking claim and its essential elements.
  5. Request an invalidity analysis for any blocking claim, including prosecution history review.
  6. Obtain a written opinion that addresses both the molecule and the intended use.
  7. Update the FTO opinion at each major development milestone: IND filing, Phase I initiation, and before any licensing negotiation.

A professional FTO opinion typically takes four to eight weeks from briefing to delivery, depending on the complexity of the landscape. Internal searches using free databases can be completed faster but carry more risk; use them for early-stage triage, not as a substitute for a defensible written opinion before commercialisation.

How regulatory exclusivities interact with patent rights in Canada

Patents and regulatory protections are legally distinct but commercially complementary. A peptide therapeutic that reaches Health Canada approval may benefit from three overlapping layers of exclusivity: patent protection, data protection under the Food and Drug Regulations, and a Certificate of Supplementary Protection (CSP). Planning all three in parallel from the filing stage is not optional for a well-run biopharma programme.

PM(NOC) basics

The Patented Medicines (Notice of Compliance) Regulations create a linkage mechanism between Health Canada’s drug approval process and patent rights. An innovator can list eligible patents on the Patent Register maintained by Health Canada. When a generic or biosimilar manufacturer files an abbreviated new drug submission referencing the innovator’s data, it must address each listed patent. This triggers either a 24-month automatic stay of the Notice of Compliance or litigation in Federal Court, giving the innovator time to enforce before a generic enters the market.

For a peptide therapeutic, the patents most likely to qualify for PM(NOC) listing are those claiming the medicinal ingredient itself, a formulation, or a use. Process patents and patents claiming only intermediates generally do not qualify.

Certificates of Supplementary Protection

A CSP can restore up to two years of patent term for a medicinal ingredient that required regulatory approval before it could be marketed in Canada, as set out in the CSP Regulations (SOR/2017-165). Eligibility requires that the patent claim the medicinal ingredient or its use, that the first Notice of Compliance for the drug was issued after the patent filing date, and that the application is filed within the prescribed window following NOC issuance.

“Patents issuing from Canadian applications have a 20-year term from filing date; a Certificate of Supplementary Protection can restore up to two years for medicinal ingredients under certain conditions.”
BLG, Life sciences & chemistry patent practice in Canada

Practical planning bullets:

  • File the patent application before or concurrent with the IND/CTA submission to preserve CSP eligibility.
  • Track the NOC issuance date; the CSP filing window is time-limited under the regulations and missing it forfeits the extension.
  • Coordinate PCT national phase entry dates with your regulatory timeline so the Canadian patent is granted before or shortly after NOC issuance.
  • Data protection under the Food and Drug Regulations runs independently of patent term; an eight-year data protection period for innovative drugs begins from the NOC date and does not require a patent.

Trade secrets, know-how, and contracts as complements to patents

Use trade secrets for manufacturing know-how and process optimisation steps that are genuinely hard to reverse-engineer. Use patents for defined molecules and uses you can disclose without destroying the competitive advantage. The two are not alternatives; they are a stack.

A peptide’s amino acid sequence, once published in a patent application, is public. The synthesis route, the purification protocol, the formulation excipient ratios, and the scale-up parameters are not necessarily disclosed in the patent and can remain trade secrets if managed correctly. That combination, a published patent on the molecule and a confidential process, is the standard commercial structure in biopharma.

Checklist for maintaining trade secrets:

  • Implement access controls: limit process documentation to personnel with a need to know and log access.
  • Maintain dated, signed lab notebooks or electronic equivalents with audit trails.
  • Require all employees, contractors, and CRO partners to sign confidentiality agreements before accessing proprietary process information.
  • Include IP ownership and confidentiality clauses in every supplier agreement, particularly for peptide API sourcing arrangements.
  • Conduct periodic trade secret audits to confirm that controls remain in place as the team grows.

Contractual protections before filing:

  • Execute a strong NDA before sharing any unpublished data with a potential partner, investor, or CRO.
  • Use material transfer agreements (MTAs) that specify IP ownership of any results generated using your peptide samples.
  • Include foreground IP assignment clauses in collaboration agreements so that inventions made during the collaboration vest in the right party from day one.

Pro Tip: Delay conference presentations and preprint submissions until after the priority date is filed. A single poster presentation before filing destroys novelty in most jurisdictions, including Canada, and cannot be undone.

Enforcement, licensing, and partnering in Canada

Enforcement paths for peptide patents in Canada run through three main channels: PM(NOC) linkage proceedings (for listed patents), infringement litigation in Federal Court, and arbitration or mediation for contractual disputes. Federal Court is the primary venue for patent infringement and validity challenges; it has specialist judges and a well-developed body of biotech case law.

Common licence structures for peptide technologies:

  • Exclusive licences with field-of-use and geographic carve-outs are standard for therapeutic applications; they command higher royalties but require diligence obligations to ensure the licensee actually develops the product.
  • Non-exclusive licences suit research tools or platform technologies where broad adoption increases the value of the IP.
  • Milestone and royalty mechanics typically include upfront payments, development milestones tied to clinical stages, and a running royalty on net sales, often with a sublicence revenue share.

Due-diligence checklist for licensors and licensees:

  1. Confirm chain of title: inventor declarations, assignment records, and any gaps in the ownership chain.
  2. Review prosecution history for any claim amendments or arguments that could limit claim scope through prosecution history estoppel.
  3. Obtain or commission an FTO opinion covering the licensee’s intended territory and use.
  4. Identify any third-party rights: co-inventor claims, government funding march-in rights, or institutional ownership interests.
  5. Review material transfer histories to confirm that no MTA restricts commercialisation of results generated using third-party materials.
  6. Confirm that all sequence listings are ST.26-compliant and that the patent register entries are current.

Practical enforcement considerations: Prosecution history estoppel can narrow the doctrine of equivalents in Canadian litigation, so claim amendments made during prosecution to overcome prior art can come back to limit enforcement. Prepare for this by preserving fallback claim positions during prosecution rather than making unnecessary amendments. For injunctive relief, Canadian courts apply a three-part test (serious issue, irreparable harm, balance of convenience); damages are available but can be difficult to quantify for early-stage therapeutics.

Canadian prosecution timeline and cost framework

Expect the drafting and filing phase to take two to four months for a complex peptide application with a full sequence listing and working examples. After filing, the Canadian prosecution timeline typically runs as follows.

Milestone Typical timing from filing date
Application publication 18 months
Request for examination deadline 4 years
First examiner’s report 6–18 months after examination request
Response deadline (per report) 4 months (extendable)
Allowance / continued examination Variable; 2–5 years total is common
Grant Shortly after allowance and payment of final fee
CSP filing window Within prescribed period after NOC issuance
PM(NOC) listing Before or at NOC issuance

High-level cost guidance (estimates only; confirm with counsel):

  • Drafting and filing a Canadian application: professional fees vary widely by complexity; a peptide application with sequence listings and multiple claim sets is at the higher end of the range for biotech filings.
  • Government filing fees: set by CIPO’s fee schedule and differ for small entities versus standard applicants; check the current CIPO fee schedule before filing.
  • Prosecution (per examiner’s report response): professional fees depend on the complexity of the objections raised.
  • PCT national phase entry into Canada: additional government and professional fees apply.

Deadlines that cannot be missed:

  • ST.26 sequence listing: at or before filing (or within the period set by CIPO if filed separately).
  • Request for examination: four years from the Canadian filing date or PCT international filing date.
  • CSP application: within the window specified in the CSP Regulations after NOC issuance.
  • PM(NOC) patent list submission: before or at the time of the NOC.

The BLG life sciences and chemistry guide provides authoritative practitioner commentary on Canadian patent term rules and biotech claim formats that is worth reviewing alongside MOPOP when preparing a filing strategy.

Canadian prosecution timeline and cost framework — overview diagram

Filing-ready checklist for peptide patents in Canada

Produce a complete package before national phase entry or a standalone Canadian filing. A dossier that arrives at CIPO with all elements in order avoids the formal requisitions that add months to prosecution and create gaps that surface during diligence.

Step-by-step checklist:

  1. Sequence listing: Prepare and validate the ST.26 XML file; confirm all sequences of four or more amino acid residues are included and numbered sequentially.
  2. Specification with working examples: Include at least one fully worked synthesis and characterisation example; prophetic examples should be clearly labelled.
  3. In vitro data package: Binding assays, activity data, selectivity panels, and stability measurements (pH, temperature, proteolytic stability).
  4. In vivo data (where available): Pharmacokinetic data, efficacy models, and toxicology summaries; include even preliminary data if it supports utility.
  5. Salt / polymorph characterisation: XRPD patterns, DSC traces, solubility data, and comparative data versus the parent compound where a derivative claim is intended.
  6. Certificates of Analysis (COAs): Batch-specific COAs from third-party testing for all peptide materials used in the experimental work; these are E-E-A-T signals in diligence and support reproducibility arguments.
  7. Inventor declarations: Signed declarations from all inventors; confirm inventorship is correct before filing.
  8. Assignment records: Executed assignments from all inventors to the applicant entity; record at CIPO promptly after filing.
  9. NDAs and MTAs: Confirm that all third-party materials used in the research were obtained under agreements that permit patent filing and commercialisation.
  10. Lab notebooks and timestamped records: Maintain dated, signed records that establish conception and reduction to practice; these are critical if priority is ever disputed.
  11. Publication and conference log: Document all public disclosures with dates to defend the priority date and confirm no pre-filing disclosures occurred.
  12. Regulatory timeline map: Align the patent filing date, PCT national phase entry, and anticipated NOC date to preserve CSP eligibility.

Document templates and administrative items:

  • CIPO inventor declaration form.
  • Assignment agreement template (reviewed by Canadian counsel).
  • NDA template with IP ownership and residuals clauses.
  • MTA template specifying foreground IP ownership and publication rights.
  • Material provenance statement for any biological materials used in the research.

Supplier quality documentation, including COAs and third-party purity reports, serves a dual purpose: it supports reproducibility arguments during prosecution and functions as a credibility signal during licensing diligence. Sourcing peptides from a supplier that provides batch-specific QC documentation is not just good lab practice; it is a filing-readiness decision.

Pro Tip: Maintain a single shared document repository with version control and access logs. Record the date of every key decision, including when you decided to file, when you received each COA, and when each experiment was completed. A clean audit trail is worth more in a contested priority dispute than any amount of retrospective documentation.

Key takeaways

Peptides are patentable in Canada when claims are drafted as physical entities with defined structure and demonstrated utility, supported by ST.26-compliant sequence listings and reproducible experimental data.

Point Details
Patentability threshold Satisfy novelty, inventive step, utility, and physicality; avoid medical-treatment framing in use claims.
sequence listing compliance File a sequence listing XML at or before filing; paper copies must be withdrawn once an electronic listing is on record.
Claim breadth vs. support File multiple claim types (molecule, composition, use, process); each must be independently supported by working examples.
Regulatory stacking Plan patent filings, CSP applications, and PM(NOC) listings in parallel with the regulatory timeline to maximise commercial exclusivity.
Peptilab documentation Peptilab supplies third-party tested peptides with batch-specific COAs that support reproducibility arguments in prosecution and licensing diligence.

A Canadian supplier’s perspective on open science and patent protection

The tension between publishing and protecting is real, and it is the question Peptilab hears most often from research teams preparing their first filing. The conventional advice is to file before you publish, which is correct but incomplete. What matters equally is the quality of the data package behind the filing, because a patent application filed with thin experimental support is a liability, not an asset, when a licensee’s counsel reviews it.

From Peptilab’s position as a Canadian supplier of research-grade peptides, the practical recommendation is this: treat your COAs, batch records, and third-party purity reports as part of your IP dossier from day one, not as afterthoughts assembled during diligence. A filing supported by documented, reproducible experimental data from well-characterised peptide materials is materially stronger than one assembled from informal lab notes and undocumented samples.

Practical recommendations for managing collaborations and supplier confidentiality:

  • Require COAs and third-party test reports for every peptide lot used in experiments that will be cited in a patent application.
  • Include confidentiality obligations in supplier agreements before sharing proprietary formulation targets or synthesis parameters.
  • Document the provenance of every material: supplier name, lot number, purity specification, and date received.
  • Coordinate publication timing with your patent counsel; a preprint posted before the priority date is a public disclosure in Canada.

Peptilab supports your IP-ready data package

Research teams preparing a Canadian peptide patent filing need more than a sequence listing and a claim draft. They need reproducible experimental data backed by documented, well-characterised materials, and that is precisely where sourcing decisions matter.

Peptilab

Peptilab supplies research-grade peptides manufactured and fulfilled in Canada, each accompanied by a batch-specific certificate of analysis from third-party testing and a purity guarantee of greater than 99%. For teams building a patent dossier or preparing for licensing diligence, that documentation is not incidental; it is the evidentiary backbone of a reproducibility argument. Peptilab also supports small-batch provision for confirmatory studies, expedited domestic shipping with no import delays, and bulk orders with consistent lot-to-lot documentation for scale-up experiments. Whether you are assembling data for a first CIPO filing, responding to an examiner’s report, or preparing a diligence package for a licensing partner, the peptide types and grades guide on the Peptilab site is a practical starting point. Contact Peptilab directly to discuss documentation requirements for your specific filing or diligence timeline.

Authoritative sources and tools for peptide IP in Canada

The sources below are the primary references for filing, searching, and regulatory coordination. Save them and consult Canadian counsel for interpretive questions; the databases and regulations are the authoritative starting point, not a substitute for professional advice.

Primary legal authorities (Canada):

Practitioner reference:

Patent and sequence search databases:

  • WIPO PatentScope / PCT: Search PCT applications and access ST.26 sequence search tools; the starting point for international landscape analysis.

This article provides general information about Canadian patent law and IP strategy for educational purposes. It is not legal advice. Consult a registered Canadian patent agent or lawyer for guidance specific to your invention and circumstances.